Skip to main content

Immunology of Diabetes V: From Bench to Bedside, Volume 1149

Immunology of Diabetes V: From Bench to Bedside, Volume 1149

Carani B. Sanjeevi (Editor), Desmond A. Schatz (Editor), Mark A. Atkinson (Editor)

ISBN: 978-1-573-31733-7

Jan 2009, Wiley-Blackwell

352 pages

Select type: Paperback

Out of stock



This volume an overview of current research in the field of immunology as it relates to diabetes. Topics covered include: autoantibody markers for type 1 diabetes; cellular immune markers for type 1 diabetes; animal models of type 1 diabetes; the pancreas in type 1 diabetes; genetics of type 1 diabetes; the role of toll-like receptors and innate immunity in type 1 diabetes; cell-based therapies for type 1 diabetes; environmental and mechanistic causes of type 1 diabetes; mechanisms of beta-cell death; role of the immune response in type 1 diabetes; and islet transplantation.

NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit

ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order ( Members of the New York Academy of Science receive full-text access to the Annals online and discounts on print volumes. Please visit for more information about becoming a member

Preface: C.B. Sanjeevi.

Part I: Special Reports:.

1. The Environmental Determinants of Diabetes in the Young (TEDDY) Study: The TEDDY Study Group and Marian Rewers.

2. Type 1 Diabetes TrialNet – An International Collaborative Clinical Trials Network: Jay S. Skyler, Carla J. Greenbaum, John M. Lachin, Ellen Leschek, Lisa Rafkin-Mervis, Peter Savage, Lisa Spain, and the Type 1 Diabetes TrialNet Study Group.

3. What will it Take to get Therapies Approved for Type 1 Diabetes?: Alexander Flemming.

Part II: The Pancreas in Type 1 Diabetes:.

4. Islet Glia, Neurons and β-cells: The Neuroimmune-Interface in Type 1 Diabetes Pathogenesis: Hubert Tsui, Shawn Winer, Yin Chan, Dorothy Truong, Lan Tang, Jason Yantha, Geoffrey Paltser, and Hans-Michael Dosch.

5. Hedgehog signalling during expansion of human Pancreatic Islet-Derived precursors: Rita Gallo, Fabio Arturo Grieco, Lorella Marselli, Elisabetta Ferretti, Alberto Gulino, Piero Marchetti and Francesco Dotta.

Part III: Update on Animal Models of Type 1 Diabetes:.

6. Humanized Mice for the Study of Type 1 Diabetes and Beta Cell Function: Marie King, Todd Pearson, Aldo A. Rossini, Leonard D. Shultz, and Dale L. Greiner.

7. Developing a Novel Model System to Target Insulin Reactive CD8 T Cells: Gwen S. Scott, Sigal Fishman, Alon Margalit, L. Khai Siew, Stephen Chapman, Li Wen, Gideon Gross, and F. Susan Wong.

8. GATA-2 Gene (Chr6、38.5cM) Locates Close to Idd20 (Chr6、37.7cM): Lowered Expressions of the NF-κB Family Members in Dendritic Cells from NOD Mice are Associated with a Reduced Expression of GATA-2: Kazuma Takahashi, Jo Satoh, and Yoshitomo Oka.

9. Measurement of CD8+ T-Cell Responses in Human Type 1 Diabetes: Emanuela Martinuzzi, François A. Lemonnier, Christian Boitard, and Roberto Mallone.

10. Comparative Analysis of the Islet Proteome Between NOD/Lt and ALR/Lt Mice: Ping Yang, Manyu Li, Dehuang Guo, Feili Gong, Bao-Ling Adam, Mark A. Atkinson and Cong-Yi Wang.

Part IV: Genetics of Type 1 Diabetes: The Next Generation:.

11. MicroRNA Genes: Are They Susceptibility Candidates for Human Type 1 Diabetes?: Li Zhou, Hongzhi He, Jenny X. Mi, Changgui Lia, Byung Lee, and Qing-Sheng Mi.

12. Independent Association of Tumor Necrosis Factor Polymorphism with Type 1 Diabetes Susceptibility: Hyoung Doo Shin, Sei Won Yang, Duk Hee Kim, and Yongsoo Park.

13. HLA Class I Supertypes in Type 1 Diabetic Children in an Urban Children’s Hospital: Zoltan Antal, Irene Jarchum, and Teresa P. DiLorenzo.

14. Congenic Mapping of the MHC-Linked Susceptibility to Type 1 Diabetes in the NOD Mouse: at Least Two Genes Contribute to the Idd16 Effect: Yoshihisa Hiromine, Tomomi Fujisawa, Shinsuke Noso, Naru Babaya, Yumiko Kawabata, and Hiroshi Ikegami.

15. STAT4 Polymorphism is Associated with Early-onset Type 1 Diabetes, but not with Late-onset Type 1 Diabetes: Hye-Soon Lee, Hyewon Park, Seiwon Yang, Dukhee Kim, and Yongsoo Park.

16. From Type 1, LADA to Type 2 Diabetes: A Continuous Spectrum? The Evidence of HLA-DQ Gene: J. Lin, Z.G. Zhou, J.P. Wang, C. Zhang, and G. Huang.

17. Molecular Scanning of the Gene for Thioredoxin, an Antioxidative and Antiapoptotic Protein, and Genetic Susceptibility to Type 1 Diabetes: Hiroshi Ikegami, Masaya Ono, Tomomi Fujisawa, Yoshihisa Hiromine, Yumiko Kawabata, and Eiji Yamato.

18. The Risk Conferred by HLA-DR and DQ for Type 1 Diabetes in 0-35 Years Age Group is not Uniform and are Different in Different Regions of Sweden: Carani B. Sanjeevi, Saikiran K Sedimbi, Mona Landin-Olsson , Ingrid Kockum, Åke Lernmark on behalf of the Swedish Childhood Diabetes and the Diabetes Incidence in Sweden Study Groups.

Part V: Toll-like Receptors and Innate Immunity in Type 1 Diabetes:.

19. The Circle between the Bedside and the Bench: Toll-Like Receptors in Models of Viral Induced Diabetes: Rita Bortell, Steven C. Pino, Dale L. Greiner, Danny Zipris, and Aldo A. Rossini.

20. Toll-like Receptors and Diabetes: F. Susan Wong and Li Wen.

21. Different KIRs Confer Susceptibility and Protection to Latent Autoimmune Diabetes in Adults in Latvian and Asian-Indian Populations: Arun Shastry, Saikiran K Sedimbi, Raja Rajalingam, Ingrida Rumba, Alok Kanungo, and CB Sanjeevi.

22. Innate Immune Pathways in Virus-Induced Autoimmune Diabetes: Anjali Nair, Travis R. Wolter, Adam J. Meyers, and Danny Zipris.

23. The Distribution of Adiponectin Receptors on Human Peripheral Blood Mononuclear Cells: Terence TL Pang and Parth Narendran.

24. The Role of Toll-Like Receptors 3 and 9 in the Development of Autoimmune Diabetes in NOD Mice: F. Susan Wong, Changyun Hu, Li Zhang, Wei Du, Lena Alexopoulou, Richard A Flavell, and Li Wen.

25. TLR Agonists Abrogate Costimulation Blockade-Induced Mixed Chimerism and Transplantation Tolerance: David M. Miller, Thomas Thornley, Todd Pearson, Masahiro Yamazaki, Michael A. Brehm, Aldo A. Rossini, and Dale L. Greiner.

Part VI: Prevention or Reversal of Type 1 Diabetes:.

26. Exendin-4 Therapy in New Onset NOD Mice Increases Regulatory T Cell Frequency: Song Xue, Clive H. Wasserfall, Matthew Parker, Todd M. Brusko, Sean McGrail, Kieran McGrail, Marcus Moore, Martha Campbell-Thompson, Desmond A. Schatz, Mark A. Atkinson, and Michael J. Haller.

27. Role of increased ROS dissipation in prevention of T1D: Lessons from the ALR mouse: Jing Chen, Aaron M Gusdon, Terri C Thayer, and Clayton E Mathews.

28. Apoptotic Non-β Cells Suppress β Cell Antigen-Reactive T Cells and Induce β Cell Antigen-Specific Regulatory T Cells: Transfusion of Apoptotic Splenic Stromal Cells Prevents Type 1 Diabetes: Chang-Qing Xia, Yushi Qiu, Ruihua Peng, Jeannette Lo-Dauer, and Michael J Clare-Salzler.

29. Persistence of Residual Beta Cells and Islet Autoimmunity During Increasing Duration of Diabetes in NOD Mice and Experimental Approaches Towards Reversing New-Onset Disease With Bioactive Peptides: Shiva Reddy, Carlos Chun Ho Cheung, Ryan Chau Chia Chai and Jessica Astrid Rodrigues.

30. TGF Plasmid Construction and Delivery for the Prevention of Type 1 Diabetes: Leejin Park, Eunjig Lee, Sangkyung Lee, Minsu Lim, Hekyung Hong, Geewook Shin, and Yongsoo Park.

31. Intravenous Administration of Murine Proinsulin1 or 2 Expressing Fiber-mutant Recombinant Adenovirus Vector Protects Diabetes in NOD Mice: Hiroaki Moriyama, Katsumi Yamada, Yasuyo Okumachi, Takashi Arai, Mami Kameno, Minoru Kishi, Hisafumi Yasuda, Kenta Haraa, Koichi Yokono, and Masao Nagata.

32. IFN-α Can Both Protect Against and Promote the Development of Type 1 Diabetes: F. Susan Wong and Li Wen.

33. Update on Worldwide Efforts to Prevent Type 1 Diabetes: Jay S. Skyler, for the Type 1 Diabetes TrialNet Study Group.

Part VII. Environmental and Mechanistic Causes of Type 1 Diabetes.

34. Tobacco exposure and diabetes related auto antibodies in children. - Results from the ABIS study: AnnaKarin Johansson, Göran Hermansson, and Johnny Ludvigsson.

35. Variations in Incidence of Type 1 Diabetes in Different Municipalities of Stockholm: Sreevalsam Gopinath, Eva Örtqvist, Svante Norgren Anders Green, And Carani B Sanjeevi.

36. Eradication of Helicobactor pylori may trigger onset of type 1 diabetes: Ai Tada, Naoko Komiya, Akira Shimada, Takeshi Katsuki, Yoichi Oikawa, and Hiroshi Itoh.

37. Diabetogenic Effects of Enteroviruses Found to be the Most Prevalent in Finnish Sewage: Paivi Klemola, Svetlana Kaijalainen, Petri Ylipaasto, and Merja Roivainen.

Part VIII: Immune Response in Islet Cell and Pancreatic Transplantation:.

38. Co-transplantation of stromal cells interferes with the rejection of allogeneic islet grafts: Stella Jacobson, Makiko Kumagai-Braesch, Annika Tibell, Mattias Svensson, and Malin Flodström-Tullberg.

39. Anti-CD20 treatment prolongs syngeneic islet graft survival and delays the onset of recurrent autoimmune diabetes: Changyun Hu, Songyan Deng, Wei Du, F. Susan Wong, and Li Wen.

40. Autologous hematopoietic stem cell transplantation for type 1 diabetes mellitus: Júlio C Voltarelli, Carlos EB Couri, Ana BPL Stracieri, Maria C Oliveira, Daniela A Moraes, Fabiano Pieroni, Marina Coutinho, Kelen CR Malmegrim, Maria C Foss-Freitas, Belinda P Simões, Milton C Foss Elizabeth Squiers, and Richard K Burt.

41. Time Course of Islet Loss After Intraportal Transplantation: Krystian Pawelec, Maciej Tadeusz Juszczak, Anila Kumar, Steve Hugh Powis, and Martin Press.

Part IX: Defining the Role of Immune Response in Type 1 Diabetes:.

42. Human Regulatory CD8+ T cells: the Involvement of Cytokines: Vitaly Ablamunits, Brygida C. Bisikirska, and Kevan C. Herold.

43. Type 1 diabetes versus type 2 diabetes with onset below 20 years: results from an Indian multicenter study: A. G. Unnikrishnan, Eesh Bhatia, Vijayalakshmi Bhatia, Sanjay Bhadada, Rakesh Kumar Sahay, Arun Kannan, V. Kumaravel, Dipti Sarma, Bantwal Ganapathy, Bantwal Ganapathy, Mathew John, R. V. Jayakumar, Harish Kumar, Vasantha Nair, and Carani B. Sanjeevi.

44. Conserved Epitopes in the Protein Tyrosine Phosphatase Family of Diabetes Autoantigens: Y. Liu, J.M. Wenzlau, L. Yu, C. Patel, G.S. Eisenbarth, J.C. Hutton, and H.W. Davidson.

45. Humoral immune response to islet autoantigens in Japanese patients with type 1 diabetes: Eiji Kawasaki, Genpei Kuriya, Tsuyoshi Satoh, Keiichiro Fujishima, Akie Moriuchi, Keiko Fukushima, Masako Ozaki, Norio Abiru, Hironori Yamasaki, and Katsumi Eguchi.

46. Identification of a major humoral epitope in Slc30A8 (ZnT8): Janet M. Wenzlau, Ong Moua, Yu Liu, George S. Eisenbarth, John C. Hutton, and Howard W. Davidson.

47. SlC30A8 is a Major Target of Humoral Autoimmunity in Type 1 Diabetes and a Predictive Marker in Prediabetes: Janet M. Wenzlau, Ong Moua, Suparna A. Sarkar, Liping Yu, Marian Rewers, George S. Eisenbarth, Howard W. Davidson, and John C. Hutton.

48. Prevalence of Organ Specific Autoantibodies in Childhood and Adulthood Onset Type 1 Diabetes: S. Allen, J. Huber, and D. Devendra.

49. Carboxypeptidase-H Autoantibodies Discriminate a More Latent Subset of Autoimmune Diabetes from Phenotypic Type 2 Diabetes among Chinese Adults: L. Yang, Z.G. Zhou, S.Z. Tan, G. Huang, P. Jin, X. Yan, X. Li, H. Peng, and W. Hagopian.

50. A Case of Latent Autoimmune Diabetes in Adult (Lada) Followed-Up Including Change of Reactivity to GAD65 Antibody Epitope From IGT to IDDM Stage Over 9 Years: Taro Maruyama, Ayako Koyama, and Christiane S. Hampe.

51. The sentinel role of CD8 T cells in regulating CD4 T cell responses to proinsulin in beta–islet cell autoimmunity: Vedran Batarelo and Ivana Durinovic-Belló.

52. Diverse FOXP3 expression in children with type 1 diabetes and coeliac disease: Anna Kivling, Lennart Nilsson, Karin Fälth-Magnusson, Sofia Söllvander, Calle Johanson, and Maria Faresjö.

53. Autoreactive T cell response in CD25 negative fraction of peripheral blood mononuclear cells from established type 1 diabetes: Hiroaki Moriyama, Reiko Kotani, Atsumi Katsuta, Mami Kameno, Takashi Arai, Yasuyo Okumachi, Minoru Kishi, Katsumi Yamada, Hisafumi Yasuda, Kenta Hara, Koichi Yokono, And Masao Nagata.

54. Gene Expression Profiles Stratified According to the Type 1 Diabetes Mellitus Susceptibility Regions: Diane Meyre Rassi, Cristina Moraes Junta, Ana Lúcia Fachin, Paula Sandrin-Garcia, Stephano Mello, Guilherme Liberato Silva, Adriane Feijó Evangelista, Danielle Aparecida Magalhães, Isabela Jubé Wastowski, Janaína Oliveira Crispim,. Gustavo Martelli-Palomino, Ana Paula Mores Fernandes, Maria Cristina Foss-Freitas, Milton César Foss, Christiane Pienna Soares, Elza Tieme Sakamoto-Hojo, Geraldo Aleixo Silva Passos, and Eduardo Antônio Donadi.

Part X: Natural History of Type 1 Diabetes:.

55. Importance of the methodological approach in the evaluation of cytokine production from peripheral blood mononuclear cell of type 1 diabetic patients: Maria Cristina Foss-Freitas, Norma Tiraboschi Foss, Diane Meyre Rassi, Eduardo Antônio Donadi, and Milton C Foss.

56. Insulitis in Human Type 1 Diabetes: Toshiaki Hanafusa and Akihisa Imagawa.

57. Immunoregulatory Pathways Controlling Progression of Autoimmunity in NOD Mice: The Role of CTLA-4 And TGF-β: Sylvaine You, Marie-Alexandra Alyanakian, Berta Segovia, Diane Damotte, Jeffrey Bluestone, Jean-François Bach, and Lucienne Chatenoud.

58. Advanced Glycation Endproducts (AGEs), important mediator of chronic complication of diabetes mellitus, induce apoptosis of cells of pancreas: Minsu Lim, Leejin Park, Geewook Shin, Hekyung Hong, Incheol Kang, and Yongsoo Park.

Part XI: Short Communications:.

59. Preparation and testing of diabetes autoantibody controls: H Brooking, MJ Powell, M Amoroso, C Betterle, B Pedini, G Coco, J Furmaniak, and B Rees Smith.

60. Tumor Necrosis Factor Alpha Induced Spatial Interactions Between Calcium Sensing Receptor and L-type Voltage Dependent Calcium Channel: Jai Parkash.

61. Tracking Down Immune Marker from Alternative System Pathway Factors of Diabetic Population: Bushra Chaudhry, Kausar Saboohi, Nazema Ahsen, and Najamul Islam.

Index of Contributors.